key: cord-0768144-hu8art75
authors: Gao, L.; Zhou, J.; Yang, S.; Chen, X.; Yang, Y.; Li, R.; Pan, Z.; Zhao, J.; Li, Z.; Huang, Q.; Tang, J.; Hu, L.; Liu, P.; Zhang, G.; Chen, Y.; Ye, L.
title: The dichotomous and incomplete adaptive immunity in COVID-19
date: 2020-09-07
journal: nan
DOI: 10.1101/2020.09.05.20187435
sha: e111e8e4c1f743e9b5ee5ac5901ae397240237e3
doc_id: 768144
cord_uid: hu8art75

The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is also not well studied. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses in 10 asymptomatic patients and 49 patients with other disease severity (mild, n=10, moderate, n=32, severe, n=7) and found that asymptomatic or mild symptomatic patients failed to mount virus-specific germinal center (GC) B cell responses that result in robust and long-term humoral immunity, assessed by GC response indicators including follicular helper T (TFH) cell and memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients mounted potent virus-specific TH1 and CD8+ T cell responses. In sharp contrast, patients of moderate or severe disease induced vigorous virus-specific GC B cell responses and associated TFH responses; however, the virus-specific TH1 and CD8+ T cells were minimally induced in these patients. These results therefore uncovered the protective immunity in asymptomatic patients and revealed the strikingly dichotomous and unbalanced humoral and cellular immune responses in COVID-19 patients with different disease severity, providing important insights into rational design of COVID-19 vaccines.

Summary 45 The adaptive immunity that protects patients from coronavirus disease 2019 , 46 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well 47 characterized. In particular, the asymptomatic patients have been found to induce weak and 48 transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; 49 meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is 50 also not well studied. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses 51 in 10 asymptomatic patients and 49 patients with other disease severity (mild, n=10, moderate, 52 n=32, severe, n=7) and found that asymptomatic or mild symptomatic patients failed to mount 53 virus-specific germinal center (GC) B cell responses that result in robust and long-term humoral 54 immunity, assessed by GC response indicators including follicular helper T (TFH) cell and 55 memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients 56 mounted potent virus-specific TH1 and CD8 + T cell responses. In sharp contrast, patients of 57 moderate or severe disease induced vigorous virus-specific GC B cell responses and associated 58 TFH responses; however, the virus-specific TH1 and CD8 + T cells were minimally induced in 59 these patients. These results therefore uncovered the protective immunity in COVID-19 patients 60 and revealed the strikingly dichotomous and incomplete adaptive immunity in COVID-19 61 patients with different disease severity, providing important insights into rational design of 62 COVID-19 vaccines. 63 Introduction with moderate or severe symptoms compared to those in recovered patients of 139 asymptomatic or mild illness ( Figure. 1A, 1C). Coincident with these results, we also 140 observed a substantial enhanced S1/S2-specific memory B cell population 141 (IgD low CD19 + S1 + /S2 + CD27 hi ) in patients with moderate (about 10% of S1/S2-specific 142 B cells) or severe disease (about 25% of S1/S2-specific B cells), while memory B-cell 143 fractions were scarcely shown in patients of asymptomatic or mild illness ( Figure. 1B, 144 1D). In line with these results, we found S1/S2-specific IgG titers highest in sera of analysis revealed the high relevance between S1/S2-specific IgG antibodies and total 165 B-cell frequencies, CXCL13 concentration and frequencies of cTFH ( Figure. S2A-S2F). 166 We also observed the high correlation between CXCL13 concentration and frequencies is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint Transient SARS-CoV-2-specific B cell response in asymptomatic individuals 170 Given the failure of inducing prolonged SARS-CoV-2-specific B-cell responses by 171 asymptomatic or mild patients, we wonder whether these patients have mounted 172 transient virus-specific B-cell responses during their hospitalization. To this end, we 173 first analyzed S1-or S2-specific B cell frequencies in their PBMCs at different time 174 points during hospitalization. We found that the peak of S1/S2-specific B cell responses 175 was induced at early stage (day 0-3) of hospitalization, which rapidly waned at the 176 middle and convalescent stages ( Figure. observations, we also noticed the relatively higher S1-and S2-specific IgG titers at the 181 middle stage (5-10 day post hospitalization) of hospitalization than those at both early 182 (0-3 day post hospitalization) and convalescent stages (more than 10 days after COVID- In addition to B-cell associated humoral immunity, the cellular immunity mediated by is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint TH1 and cytotoxic CD8 + T lymphocytes also plays a critical role in the control of viral is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. To further assess the cytolytic functionality of virus-specific CD8 + T cells in COVID-236 19 patients, we first gated on virus-specific IFN-γ + CD8 + T cells, followed by measuring 237 the frequencies of cells capable of producing GZMB and perforin. We found that in 238 asymptomatic or mild symptomatic patients, approximate 60% of IFN-γ + CD8 + T cells 239 simultaneously produced GZMB and perforin, whereas only 12% or 3% of IFN-γ + 240 CD8 + T cells were able to make both cytolytic molecules in moderate or severe patients 241 ( Figure. 3G, 3H). These data therefore revealed that albeit the failure in mounting 242 SARS-CoV-2-specific humoral immunity, asymptomatic or mild symptomatic patients 243 were able to induce a profound virus-specific cellular (TH1 and CD8 + T cell) immunity.

In sharp contrast, patients of moderate or severe disease were able to generate potent 245 SARS-CoV-2-specific humoral immunity, but they failed to induce effective virus- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. IgG-secreting plasma cells were almost absent in these patients. These results therefore 271 explained the phenomenon that asymptomatic patients failed to generate and maintain 272 a long-term SARS-CoV-2-specific IgG response.

In contrast to humoral immunity, we found that the virus-specific TH1 and CD8 + T 274 cell immune responses were rapidly induced and sustained in asymptomatic or mild 275 symptomatic patients as compared to patients with moderate or severe disease, which 276 presumably protect them from progressing to severe COVID-19. We also envision that 277 the rapid and robust virus-specific TH1 and CD8 + T cell responses may effectively 278 curtail the SARS-CoV-2 replication, which results in the inefficient viral antigen 279 production and limits the GC reaction that requires sufficient antigen stimulation. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint infection with pre-existing SARS-CoV-2 cross-reactive T cells could determine the 289 clinically asymptomatic state in COVID-19 patients.

In summary, we revealed a striking dichotomous pattern of humoral and cellular 291 immunity induced in patients of asymptomatic/mild or moderate/severe disease. The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint (CD27 hi IgD low ), gated on S1 or S2 specific B cells (S1 + /S2 + CD19 + ) shown in A.

C & D, Percentages of S1 or S2 specific B cells (C), summarized from (A); and S1 or is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint

Figure 3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint at 4°C, followed by washing with perm/wash buffer (BD) and intracellular stained for 681 30 minutes on ice. Antibodies used in this assay were listed in Table S7 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint Table S1 . Characteristics of patients in this study 780 1. Continuous variables were shown as the median (interquartile range, IQR). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. 

In her 40s Female 29 14 #9

In her 30s Female 14 12 #10

In her 60s Female 18 12 #11

In his 60s Male 19 11 #12

In her 60s Female 17 13 #13

In her 60s Female 10 14 #14

In her 20s Female 11 12 #15

In his 40s Male 8 10 #16

In his 30s Male 11 10 #17

In her 50s Female 24 12 #18

In her 60s Female 20 11 #19

In his 30s Male 13 12 #20

In her 30s Female 25 14 #21

In is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.05.20187435 doi: medRxiv preprint

Correlations between B cells frequency and S1-(a) or S2-(b) specific IgG levels

Correlations between serum CXCL13 concentration and S1-(c) or S2-(d) specific

Correlations between cTFH cells frequency and S1-(e) or S2-(f) specific IgG levels

Correlations between cTFH cells frequency and serum CXCL13 concentration

Statistical comparisons were performed using Spearman correlation analysis

P values of Figure 1c

. Early

Early Middle Convalescence Healthy / *** *** ***